new 12 month closing high, page-34

ESP, welcome aboard!

Though I believe its best not to bundle ADO with other micro cap biotechs in your head. I am certainly not treating it as such.

I like to think of our position as fairly analagous to a young mining services company.

You know the old gold rush saying: "who made more from the gold rush, the guys digging the gold or the ones selling the picks?".

We are not the ones prospecting for gold (eg. companies searching for a cure for cancer/aids/long shot FDA approval etc etc), ADO is simply selling a vital ingredient to these prospectors so they can do their job better.

So as these guys sell more products, so do we. But importantly if they fail (as many do), we dont.

This is why I dont see ADO as one of those risky penny-dreadful type biotechs, we are simply a young Monadelphous waiting for our early contracts!